FDA Clears MannKind’s Furoscix ReadyFlow — Company Raises $50M to Cover Milestone Payment

Following FDA clearance of Furoscix ReadyFlow for heart failure and CKD edema, MannKind secures $50 million to fund the $45M milestone payment.